Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franziska Haderk

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Cancers|December 1, 2017
Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung CancerWei Wu, Franziska Haderk, Trever G Bivona
Methods in Molecular Biology (Clifton, N.J.)|December 20, 2018
Immunohistochemistry to Study YAP in Human Tissue SamplesFranziska Haderk, Victor Olivas, Trever G Bivona
Current Opinion in Chemical Biology|January 8, 2021
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironmentD Lucas Kerr, Franziska Haderk, Trever G Bivona
Journal of Visualized Experiments : Jove|December 6, 2021
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived OrganoidsDora Barbosa Rabago, Collin M Blakely, Franziska Haderk, et al.
Leukemia & Lymphoma|July 16, 2013
Extracellular vesicles in chronic lymphocytic leukemiaFranziska Haderk, Bola Hanna, Karsten Richter, et al.
Journal of Extracellular Vesicles|May 28, 2026
Extracellular Vesicles as Enabling Biomarkers for New Approach Methodologies to Support the US Food and Drug Administration Modernization Act 3.0Andrew Rowland, Carl Kirkpatrick, A David Rodrigues, et al.
Blood|June 24, 2015
Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblastsJerome Paggetti, Franziska Haderk, Martina Seiffert, et al.
Neuro-Oncology|November 4, 2019
Betacellulin drives therapy resistance in glioblastomaQiwen Fan, Zhenyi An, Robyn A Wong, et al.
Cancer Research|February 23, 2022
Understanding Drug Sensitivity and Tackling Resistance in CancerJeffrey W Tyner, Franziska Haderk, Anbarasu Kumaraswamy, et al.
Cancer Research Communications|April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study FindingsJames J Harding, Ralf Hofheinz, Elena Élez, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Cancers|December 1, 2017
Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung CancerWei Wu, Franziska Haderk, Trever G Bivona
Methods in Molecular Biology (Clifton, N.J.)|December 20, 2018
Immunohistochemistry to Study YAP in Human Tissue SamplesFranziska Haderk, Victor Olivas, Trever G Bivona
Current Opinion in Chemical Biology|January 8, 2021
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironmentD Lucas Kerr, Franziska Haderk, Trever G Bivona
Journal of Visualized Experiments : Jove|December 6, 2021
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived OrganoidsDora Barbosa Rabago, Collin M Blakely, Franziska Haderk, et al.
Leukemia & Lymphoma|July 16, 2013
Extracellular vesicles in chronic lymphocytic leukemiaFranziska Haderk, Bola Hanna, Karsten Richter, et al.
Journal of Extracellular Vesicles|May 28, 2026
Extracellular Vesicles as Enabling Biomarkers for New Approach Methodologies to Support the US Food and Drug Administration Modernization Act 3.0Andrew Rowland, Carl Kirkpatrick, A David Rodrigues, et al.
Blood|June 24, 2015
Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblastsJerome Paggetti, Franziska Haderk, Martina Seiffert, et al.
Neuro-Oncology|November 4, 2019
Betacellulin drives therapy resistance in glioblastomaQiwen Fan, Zhenyi An, Robyn A Wong, et al.
Cancer Research|February 23, 2022
Understanding Drug Sensitivity and Tackling Resistance in CancerJeffrey W Tyner, Franziska Haderk, Anbarasu Kumaraswamy, et al.
Cancer Research Communications|April 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study FindingsJames J Harding, Ralf Hofheinz, Elena Élez, et al.
Pageof 2